Michelsen, B. Et Al. 2022. Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.. Arthritis care & research , vol.74, no.7 , 1205-1218.

Michelsen, B., Georgiadis, S., Di Giuseppe, D., Loft, A. G., Nissen, M. J., Iannone, F., ... Pombo-Suarez, M.(2022). Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.. Arthritis care & research , vol.74, no.7, 1205-1218.

Michelsen, Brigitte Et Al. "Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.," Arthritis care & research , vol.74, no.7, 1205-1218, 2022

Michelsen, Brigitte Et Al. "Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.." Arthritis care & research , vol.74, no.7, pp.1205-1218, 2022

Michelsen, B. Et Al. (2022) . "Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.." Arthritis care & research , vol.74, no.7, pp.1205-1218.

@article{article, author={Brigitte Michelsen Et Al. }, title={Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.}, journal={Arthritis care & research}, year=2022, pages={1205-1218} }